Clinical Effects of Temperature Controlled Laminar Airflow (TLA)

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

June 30, 2006

Conditions
AsthmaPerennial Allergy
Interventions
DEVICE

Temperature controlled Laminar Airflow (Protexo)

The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.

DEVICE

Placebo TLA

TLA treatment with disabled filtration function

Trial Locations (2)

SE-581 91

University Hospital, Linkoeping, Linköping

SE-171 76

Karolinska University Hospital, Stockholm

All Listed Sponsors
collaborator

Karolinska University Hospital

OTHER

collaborator

University Hospital, Linkoeping

OTHER

collaborator

Quintiles, Inc.

INDUSTRY

lead

Airsonett AB

INDUSTRY

NCT00987064 - Clinical Effects of Temperature Controlled Laminar Airflow (TLA) | Biotech Hunter | Biotech Hunter